Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine
/ Icahn School of Medicine at Mount Sinai
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 15, 2022
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
(clinicaltrials.gov)
- P2 | N=36 | Completed | Sponsor: Nina Bhardwaj | Active, not recruiting ➔ Completed
Trial completion • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • CTAG1B
1 to 1
Of
1
Go to page
1